Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 58 matching trials from the live ClinicalTrials.gov search.
Enrolling by invitation Phase 3 Interventional

Protest Trial: TXA vs Saline

NCT06422273
Conditions
Lung Transplant, Complications Surgical
Interventions
Tranexamic Acid, Saline (placebo)
Drug · Other
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Conditions
Hemostasis, General Surgery
Interventions
sFilm-FS, TACHOSIL®
Combination Product
Lead sponsor
Sealantium Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more
Conditions
Scoliosis, Kyphosis, Lordosis, Spondylitis, Spinal Stenosis
Interventions
Epsilon-Aminocaproic Acid (EACA), Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
ecallantide, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
Recruiting Phase 4 Interventional

sTErnAl heMostasiS Trial

NCT06511778
Conditions
Excessive Bleeding During Surgery
Interventions
Hemoblast Bellows application
Drug
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed No phase listed Observational

Electronic Catheter Stethoscope

NCT01463462
Conditions
Pelvic Organ Prolapse, Gynecologic Cancers, Uterine Leiomyomata, Adenomyosis, Endometrial Hyperplasia, Other Abnormal Uterine and Vaginal Bleeding, Pelvic Mass, Pelvic Pain
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1, Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Congenital Fibrinogen Deficiency
Interventions
Octafibrin
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Miami, Florida
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
13 Years to 70 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Conditions
Hypotensive Anesthesia, Orthognathic Surgery
Interventions
Dexmedetomidine, Nicardipine, Labetalol
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Misoprostol for Reduction of Blood Loss During Fibroid Surgery

NCT02209545
Conditions
Fibroids
Interventions
Misoprostol, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cesarean Sections
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sacramento, California
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Conditions
Hemostasis, Hemostatic Techniques
Interventions
ETHIZIA, SURGICEL Original
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
22 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Los Angeles, California • St Louis, Missouri • Pennington, New Jersey + 3 more
Conditions
Intraoperative Bleeding
Interventions
Epinephrine, Normal Saline irrigation fluid
Drug · Procedure
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sayre, Pennsylvania
Conditions
Blood Loss
Interventions
Hemostatic Matrix
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Blood Loss, Surgical
Interventions
Fibrin Sealant 2 (FS2), Oxidized Regenerated Cellulose (Surgicel)
Drug · Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
16
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 12 more
Conditions
Excessive Bleeding During Surgery
Interventions
Fibrin Sealant Grifols, EVICEL
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Up to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more
Conditions
Blood Loss, Surgical
Interventions
Vasopressin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions
standard therapy, activated recombinant human factor VII, placebo
Procedure · Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intraoperative Bleeding During Endoscopic Sinus Surgery

NCT01014728
Conditions
Blood Loss
Interventions
propofol, sevoflurane
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Blood Loss, Surgical
Interventions
Ecallantide, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 16 more